PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer

Abstract The inherent or acquired resistance to paclitaxel and cisplatin, which are commonly used chemotherapeutic agents for ovarian cancer treatment, remains an important issue in chemotherapy of multidrug resistant ovarian cancer. Currently, it is still challenging to deal with the recurrent or a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chitra Risnayanti, Yeong-Su Jang, Jinju Lee, Hyung Jun Ahn
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5e5b7dd851f146bfa3ba1c69156de556
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5e5b7dd851f146bfa3ba1c69156de556
record_format	dspace
spelling	oai:doaj.org-article:5e5b7dd851f146bfa3ba1c69156de5562021-12-02T16:08:14ZPLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer10.1038/s41598-018-25930-72045-2322https://doaj.org/article/5e5b7dd851f146bfa3ba1c69156de5562018-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-25930-7https://doaj.org/toc/2045-2322Abstract The inherent or acquired resistance to paclitaxel and cisplatin, which are commonly used chemotherapeutic agents for ovarian cancer treatment, remains an important issue in chemotherapy of multidrug resistant ovarian cancer. Currently, it is still challenging to deal with the recurrent or advanced stage ovarian cancer. When drug efflux and anti-apoptotic pathways are highly interdependent and also involved in developing the resistance of multidrug resistant ovarian cancer, simultaneous inhibition of both pathways represents the potential targets to enhance the efficacy of chemotherapy. Here, we introduce PLGA nanoparticles system as a “dual RNAi delivery system” to contain both MDR1 and BCL2 siRNA, which is designed for simultaneous inhibition of drug efflux and cell death defense pathways. In the present studies, siRNA-loaded PLGA nanoparticles efficiently elicit the simultaneous suppression of both genes, which consequently shows more enhanced drug-sensitivity than sole suppression of drug efflux or anti-apoptosis in the resistant ovarian cancer cells, owing to the interdependence of both pathways. Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and cisplatin on the paclitaxel-resistant SKOV3-TR and cisplatin-resistant A2780-CP20 ovarian cancer respectively.Chitra RisnayantiYeong-Su JangJinju LeeHyung Jun AhnNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-12 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Chitra Risnayanti Yeong-Su Jang Jinju Lee Hyung Jun Ahn PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer
description	Abstract The inherent or acquired resistance to paclitaxel and cisplatin, which are commonly used chemotherapeutic agents for ovarian cancer treatment, remains an important issue in chemotherapy of multidrug resistant ovarian cancer. Currently, it is still challenging to deal with the recurrent or advanced stage ovarian cancer. When drug efflux and anti-apoptotic pathways are highly interdependent and also involved in developing the resistance of multidrug resistant ovarian cancer, simultaneous inhibition of both pathways represents the potential targets to enhance the efficacy of chemotherapy. Here, we introduce PLGA nanoparticles system as a “dual RNAi delivery system” to contain both MDR1 and BCL2 siRNA, which is designed for simultaneous inhibition of drug efflux and cell death defense pathways. In the present studies, siRNA-loaded PLGA nanoparticles efficiently elicit the simultaneous suppression of both genes, which consequently shows more enhanced drug-sensitivity than sole suppression of drug efflux or anti-apoptosis in the resistant ovarian cancer cells, owing to the interdependence of both pathways. Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and cisplatin on the paclitaxel-resistant SKOV3-TR and cisplatin-resistant A2780-CP20 ovarian cancer respectively.
format	article
author	Chitra Risnayanti Yeong-Su Jang Jinju Lee Hyung Jun Ahn
author_facet	Chitra Risnayanti Yeong-Su Jang Jinju Lee Hyung Jun Ahn
author_sort	Chitra Risnayanti
title	PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer
title_short	PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer
title_full	PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer
title_fullStr	PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer
title_full_unstemmed	PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer
title_sort	plga nanoparticles co-delivering mdr1 and bcl2 sirna for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/5e5b7dd851f146bfa3ba1c69156de556
work_keys_str_mv	AT chitrarisnayanti plgananoparticlescodeliveringmdr1andbcl2sirnaforovercomingresistanceofpaclitaxelandcisplatininrecurrentoradvancedovariancancer AT yeongsujang plgananoparticlescodeliveringmdr1andbcl2sirnaforovercomingresistanceofpaclitaxelandcisplatininrecurrentoradvancedovariancancer AT jinjulee plgananoparticlescodeliveringmdr1andbcl2sirnaforovercomingresistanceofpaclitaxelandcisplatininrecurrentoradvancedovariancancer AT hyungjunahn plgananoparticlescodeliveringmdr1andbcl2sirnaforovercomingresistanceofpaclitaxelandcisplatininrecurrentoradvancedovariancancer
_version_	1718384531303563264

PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer

Ejemplares similares